- Home
- MATV vs GOSS Comparison
MATV vs GOSS Comparison
Compare MATV & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MATV | GOSS |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.0M | 796.2M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MATV | GOSS |
|---|---|---|
| Price | $12.16 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $10.00 | $8.60 |
| AVG Volume (30 Days) | 306.7K | ★ 4.5M |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,982,500,000.00 | $44,051,000.00 |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $2.26 | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $4.34 | $0.76 |
| 52 Week High | $13.57 | $3.87 |
Technical Indicators
Market Signals| Indicator | MATV | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 45.93 |
| Support Level | $11.90 | $3.04 |
| Resistance Level | $12.45 | $3.87 |
| Average True Range (ATR) | 0.42 | 0.29 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 22.73 | 11.45 |
Price Performance
Historical ComparisonAbout MATV Mativ Holdings Inc.
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments namely Filtration & advanced Materials focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging and healthcare solutions.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.